KR100690928B1 - Method for separation and purification of epigallocatechin gallate - Google Patents
Method for separation and purification of epigallocatechin gallate Download PDFInfo
- Publication number
- KR100690928B1 KR100690928B1 KR1020040097357A KR20040097357A KR100690928B1 KR 100690928 B1 KR100690928 B1 KR 100690928B1 KR 1020040097357 A KR1020040097357 A KR 1020040097357A KR 20040097357 A KR20040097357 A KR 20040097357A KR 100690928 B1 KR100690928 B1 KR 100690928B1
- Authority
- KR
- South Korea
- Prior art keywords
- epigallocatechin gallate
- filler
- column
- green tea
- separation
- Prior art date
Links
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 229940030275 epigallocatechin gallate Drugs 0.000 title claims abstract description 80
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000000926 separation method Methods 0.000 title claims abstract description 19
- 238000000746 purification Methods 0.000 title claims abstract description 10
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 29
- 229940094952 green tea extract Drugs 0.000 claims abstract description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 75
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 239000000945 filler Substances 0.000 claims description 33
- 239000007864 aqueous solution Substances 0.000 claims description 22
- 244000269722 Thea sinensis Species 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- 235000009569 green tea Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- UWGIJJRGSGDBFJ-UHFFFAOYSA-N dichloromethylsilane Chemical group [SiH3]C(Cl)Cl UWGIJJRGSGDBFJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 abstract description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 15
- 235000005487 catechin Nutrition 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 12
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 11
- 229950001002 cianidanol Drugs 0.000 description 11
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 11
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 10
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229960001948 caffeine Drugs 0.000 description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 6
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 4
- 235000012734 epicatechin Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 2
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- -1 antioxidants Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229930013799 (-)-catechin Natural products 0.000 description 1
- 235000007331 (-)-catechin Nutrition 0.000 description 1
- XMOCLSLCDHWDHP-DOMZBBRYSA-N (-)-gallocatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-DOMZBBRYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920000571 Nylon 11 Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical group C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Abstract
본 발명은 녹차 추출물로부터 활성이 가장 큰 물질로 알려진 에피갈로카테킨 갈레이트(epigallocatechin gallate: EGCG)를 고순도로 대량 분리 정제하는 방법에 관한 것이다. The present invention relates to a method for high-volume separation and purification of epigallocatechin gallate (EGCG), which is known to be the most active substance from green tea extract.
녹차 추출물, 에피갈로카테킨 갈레이트, DM 1020 칼럼, C-18 ODS 칼럼 Green Tea Extract, Epigallocatechin Gallate, DM 1020 Column, C-18 ODS Column
Description
도 1에서 Ⅰ은 카테킨, Ⅱ는 갈로카테킨, Ⅲ은 에피카테킨, Ⅳ는 에피카테킨 갈레이트, Ⅴ는 에피갈로카테킨, 그리고 Ⅵ는 에피갈로카테킨 갈레이트의 구조를 나타낸다. In Figure 1 I is catechin, II is gallocatechin, III is epicatechin, IV is epicatechin gallate, V is epigallocatechin, and VI is epigallocatechin gallate.
도 2는 DM 1020의 구조를 나타내고, 여기서 n은 평균 5이다. 2 shows the structure of DM 1020, where n is 5 on average.
도 3은 정제된 에피갈로카테킨 갈레이트의 HPLC 차트를 나타낸다. 3 shows an HPLC chart of purified epigallocatechin gallate.
본 발명은 녹차 추출물로부터 활성이 가장 큰 물질로 알려진 에피갈로카테킨 갈레이트(epigallocatechin gallate: EGCG)를 고순도로 대량 분리 정제하는 방법에 관한 것이다. The present invention relates to a method for high-volume separation and purification of epigallocatechin gallate (EGCG), which is known to be the most active substance from green tea extract.
약 5000년 전부터 음용되어온 녹차는 혈액 순환을 증진시키고, 체내의 독성물질을 제거하며, 각종 질병에 대한 저항성을 높여주는 것으로 인식되어 있다. 최근 수년간 이러한 녹차의 효능에 대하여 과학적으로 입증하려는 많은 중요한 연구 가 진행되었으며, 현재도 그 효능에 대한 연구가 꾸준히 이루어지고 있다.Green tea, which has been drinking for about 5000 years, is recognized to improve blood circulation, remove toxic substances in the body, and increase resistance to various diseases. In recent years, many important researches have been conducted to scientifically prove the efficacy of green tea, and the research on the efficacy of the green tea has been continuously conducted.
시험관내(in vitro) 및 생체내(in vivo) 실험들은 녹차의 효능을 발휘하는 성분은 카테킨이며, 상기 카테킨 성분 중 에피갈로카테킨 갈레이트라는 물질의 활성이 가장 크다고 보고하였다(A review of the latest research findings on the health promotion properties of tea, Christiane J. Dufresne, Edward R. Farnworth, J. Nutr. Bichem, 2001. 12, 404~421)In vitro and in vivo experiments reported that catechin is the most effective ingredient of green tea, and epigallocatechin gallate has the highest activity among the catechin components (A review of the latest research findings on the health promotion properties of tea, Christiane J. Dufresne, Edward R. Farnworth, J. Nutr. Bichem, 2001. 12, 404--421)
녹차 카테틴의 성분으로는 6가지가 알려져 있는데, 이들은 카테킨(catechin), 갈로카테킨(gallocatechin: GC), 에피카테킨(epicatechin: EC), 에피카테킨 갈레이트(epicatechin gallate: ECG), 에피갈로카테킨(epigallocatechin: EGC), 그리고 에피갈로카테킨 갈레이트로서, 상기 화합물의 구조를 도 1에 나타내었다. Six types of green tea catechins are known, which are catechin, gallocatechin (GC), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin (epigallocatechin). : EGC), and epigallocatechin gallate, the structure of the compound is shown in FIG. 1.
녹차에 함유된 카테킨의 함량은 일반적으로 차 재배지역의 기후 및 토양 등의 재배환경과 채취시기에 따라 성분의 함량과 조성비율이 다르게 나타나지만, 카테킨 함량은 평균적으로 차 잎의 총 건중량 대비 10~15%이며, 가장 강력한 활성을 지닌 것으로 평가되고 있는 에피갈로카테킨 갈레이트가 카테킨 성분 중 50~60%를 차지하고 있다(지리산 야생녹차의 화학성분, 신미경, 한국차문화 협회지, 2000년 3~4월호, 30~33).Although the content of catechin in green tea generally varies depending on the cultivation environment and harvesting time of the tea growing area, the content and composition ratio of catechin are different, but on average, the catechin content is 10 ~ 15 of the total dry weight of tea leaves. %, And epigallocatechin gallate, which is considered to have the strongest activity, accounts for 50 to 60% of catechin components (chemical composition of Jiri wild green tea, Shin Mi-kyung, Korean Tea Culture Association, March-April 2000) , 30-33).
이들 녹차 카테킨에 대하여 항산화, 항암, 항균, 콜레스테롤 저하, 심장혈관 질환 억제, 비만 억제, 피부미용, 중금속 제거와 충치 및 치주염 예방 등 다양한 효능들이 임상시험 결과 보고되었으며, 카테킨 중에서 에피갈로카테킨 갈레이트는 가장 활성이 뛰어난 물질로 평가되고 있다. Various results have been reported for these green tea catechins, including antioxidants, anticancer, antibacterial, cholesterol lowering, cardiovascular disease suppression, obesity suppression, skin care, heavy metal removal and tooth decay and periodontitis. Among the catechins, epigallocatechin gallate Is considered to be the most active substance.
에피갈로카테킨 갈레이트는 비타민 C보다 약 20배 이상의 항산화력을 나타내는 것으로 보고되고 있으며, 또한 암예방에도 뛰어난 물질로 보고되었다. 특히 정상세포에 대해서는 괴사를 일으키지 않지만 암세포에 대하여는 기형세포파괴기작(apoptosis)을 일으킨다고 보고되었다. 에피갈로카테킨 갈레이트의 이러한 선택성으로 암예방 및 치료 등에 인체를 대상으로 한 많은 실험들이 진행되고 있다. Epigallocatechin gallate has been reported to exhibit about 20 times more antioxidant activity than vitamin C, and has also been reported to be an excellent substance for cancer prevention. In particular, necrosis does not occur in normal cells, but it has been reported to cause apoptosis in cancer cells. Due to this selectivity of epigallocatechin gallate, many experiments have been conducted in humans for cancer prevention and treatment.
또한 장기간, 다량 복용에 의해서만 나타나는 녹차의 효능을 단기간의 복용으로 얻기 위해서는 가장 활성이 뛰어난 에피갈로카테킨 갈레이트의 분리가 요구되며, 따라서, 경제적이며, 생산성이 뛰어난 에피갈로카테킨 갈레이트의 고순도 분리정제 기술 개발이 요구된다.In addition, in order to obtain the efficacy of green tea, which appears only in long-term and high doses, in short-term doses, separation of the most active epigallocatechin gallate is required, and therefore, high purity of epigallocatechin gallate, which is economical and productive, is high. Separation and purification technology development is required.
지금까지 고순도 에피갈로카테킨 갈레이트의 제조 방법으로 다공성 극성 충전제, HPLC(고속액체 크로마토그래피)를 이용하여 분리하는 방법, 카페인을 첨가하여 분리하는 방법, 폴리아미드 충전제를 이용하는 분리방법 등이 제시되었다.Until now, a method of preparing high purity epigallocatechin gallate has been proposed using a porous polar filler, separation using HPLC (high-performance liquid chromatography), separation using caffeine, and separation using polyamide filler. .
한국특허공개 제2001-0050080호에서는 대공극성(macroporous) 극성 수지, 예를 들면 롬 앤드 하스(Rohm and Haas)사에서 시판하는 암베라이트(AMBERLITE, 등록상표) XAD-7과 같은 폴리아크릴레이트, 폴리메타크릴에이트, 그리고 폴리아미드 수지 상에서 녹차 추출물을 처리하여 에피갈로카테킨 갈레이트를 분리 제조하는 방법을 제시하였다. 상기 방법에서는 공정상 충전제가 채워진 칼럼의 온도를 60℃로 유 지시키는 온도 조절 장치를 사용하고 있으며, 26 kg의 암베라이트 XAD-7 수지에, 에피갈로카테킨 갈레이트 152.5 g을 함유하는 0.4 kg의 녹차 추출물을 로딩한 후, 물/이소프로판올(부피비 9:1)을 약 318 kg 용출시켜 에피갈로카테킨 갈레이트를 얻었다. 상기 방법에서 에피갈로카테킨 갈레이트를 얻는 공정에서는 다량의 물/이소프로판올(부피비 9:1)이 사용되어 상대적으로 농축설비의 거대화 등 제조 효율이 떨어지며, 또한 칼럼 온도 유지 장치의 추가적인 비용이 발생하는 문제점이 있다.Korean Patent Publication No. 2001-0050080 discloses macroporous polar resins, such as polyacrylates and polys such as AMBERLITE® XAD-7, available from Rohm and Haas. A method of separating and preparing epigallocatechin gallate by treating green tea extract on methacrylate and polyamide resin was presented. The process uses a thermostat that maintains the temperature of the column filled with filler in the process at 60 ° C. 0.4 kg containing 152.5 g of epigallocatechin gallate in 26 kg of Amberlite XAD-7 resin. After the green tea extract was loaded, about 318 kg of water / isopropanol (volume ratio 9: 1) was eluted to obtain epigallocatechin gallate. In the process of obtaining epigallocatechin gallate in the above method, a large amount of water / isopropanol (volume ratio 9: 1) is used, which leads to relatively low manufacturing efficiency, such as enlarging the enrichment equipment, and additional cost of maintaining the column temperature. There is a problem.
미국특허공고 제US04613672호에서는 용리액을 아세톤/테트라히드로푸란/클로로포름을 사용하여 C-18 역상 칼럼을 사용한 HPLC 분리법을 제시하였고, 한국특허공개 제1999-007629호에서는 충전제의 크기가 15 ㎛인 Lichrospher 100RP-18 충전제를 사용한 칼럼(250×4.60㎜)이 장착된 HPLC에 의한 에피갈로카테킨 갈레이트 분리법을 제시하였다. US Patent Publication No. US04613672 proposed an HPLC separation method using a C-18 reversed phase column using acetone / tetrahydrofuran / chloroform as eluent. Epigallocatechin gallate separation by HPLC with a column (250 × 4.60 mm) using -18 filler was presented.
상기 방법들은 일차로 테트라히드로푸란과 같은 용매를 사용하여 식품 제조상 안전성 등의 문제를 야기시키며, 또한 HPLC의 사용은 실험실적인 용도로써 대량 생산의 경우 그 제조비용 및 생산성에 대한 재평가가 이루어져야 하는 문제가 있다. These methods primarily cause problems such as safety in food manufacturing using solvents such as tetrahydrofuran. Also, the use of HPLC is a laboratory use, which requires a reassessment of the manufacturing cost and productivity for mass production. have.
미국특허공고 제US06210679호는 95% 이상의 무카페인-에피갈로카테킨 갈레이트 분리방법으로서 4 연속 공정이며, 각 공정마다 폴리아미드 또는 C-18 충전제가 충전된 칼럼을 사용하여, 제조공정이 다소 복잡한 문제가 있다.U.S. Patent Publication No. US06210679 is a method of separating more than 95% of caffeine-epigallocatechin gallate, which is a four-step process, using a column filled with polyamide or C-18 filler for each process, and the manufacturing process is rather complicated. there is a problem.
한국특허공개 제2003-0046122호에서는 녹차 추출물에 카페인을 첨가하여 에 피갈로카테킨 갈레이트와 에피카테킨 갈레이트를 선택적으로 분리한 후, 클로로포름과 같은 유기 할로겐용매를 사용하여 카페인을 제거하고, 세파덱스 HP-20과 같은 합성 흡착제를 이용한 칼럼 크로마토그래피를 실시하여, 순도 90% 이상의 에피갈로카테킨 갈레이트를 얻는 방법이 제시되었다. 상기 방법에서는 일차로 다량의 카페인이 인위적으로 추가되고, 추가된 카페인을 다시 제거하기 위해 유기 할로겐 용매가 사용되어 식품 등의 제조에 있어 안전성 평가 등에 문제가 된다.In Korean Patent Publication No. 2003-0046122, caffeine is added to green tea extract to selectively separate epigallocatechin gallate and epicatechin gallate, and then caffeine is removed using an organic halogen solvent such as chloroform, and Sephadex HP. A method of obtaining epigallocatechin gallate with a purity of 90% or more by performing column chromatography using a synthetic adsorbent such as -20 has been proposed. In the above method, a large amount of caffeine is artificially added first, and an organic halogen solvent is used to remove the added caffeine again, which is a problem in evaluating safety in the manufacture of food and the like.
따라서 인체에 대한 안전성이 보장되고 경제적이며 생산성이 높은 에피갈로카테킨 갈레이트의 분리 방법이 요구된다.Therefore, there is a need for a method of isolating epigallocatechin gallate that is safe for the human body and economical and productive.
본 발명은 상기한 바와 같은 종래의 문제점을 해결하기 위하여 안출된 것으로서, 본 발명의 목적은 녹차 추출물로부터 활성이 가장 큰 물질로 알려진 에피갈로카테킨 갈레이트를 경제적이며 고순도로 대량 분리 정제하는 방법을 제공하는 데 있다. The present invention has been made in order to solve the conventional problems as described above, an object of the present invention is to provide a method for mass separation and purification of epigallocatechin gallate known as the most active substance from green tea extracts economically and high purity To provide.
본 발명의 한 태양은 하기 단계들을 포함하는 녹차 추출물로부터 에피갈로카테킨 갈레이트를 분리정제하는 방법이다:One aspect of the invention is a method for the separation and purification of epigallocatechin gallate from green tea extract comprising the following steps:
1) 녹차 잎을 물 또는 에탄올로 가온 추출하여 분말상으로 만든 녹차 추출물을, 실리카겔에 디클로로메틸 실란을 결합시킨 충전제로서 그 크기가 100 ㎛인 충전제를 충전 매질로 사용한 칼럼을 이용하고, 0.1~5.0v/v% 아세트산 수용액 또는 1.0~20.0v/v% 에탄올 수용액을 용리액으로 이용하여 에피갈로카테킨 갈레이트를 분리정제하는 단계, 1) A green tea extract prepared by heating and extracting green tea leaves with water or ethanol into powder form, using a column using a filler having a size of 100 μm as a filling medium as a filler in which dichloromethyl silane is bonded to silica gel, and using 0.1 to 5.0 v Separation and purification of epigallocatechin gallate using an aqueous solution of / v% acetic acid or an aqueous solution of 1.0-20.0v / v% ethanol as eluent,
2) 상기 1)단계에서 분리 용출된 용출액 중 에피갈로카테킨 갈레이트를 함유하는 용출액을 농축하여 얻은 분획물을 에틸아세테이트로 추출하는 단계, 그리고2) extracting the fraction obtained by concentrating the eluate containing epigallocatechin gallate in the eluate separated and eluted in step 1) with ethyl acetate, and
3) 상기 2)단계에서 분리된 에틸아세테이트 용액을 다시 농축하여 얻은 농축물을 0.1~5.0v/v% 아세트산 수용액으로 재결정하는 단계.3) Recrystallizing the concentrate obtained by re-concentrating the ethyl acetate solution separated in step 2) with 0.1 ~ 5.0v / v% acetic acid aqueous solution.
또한, 본 발명의 에피갈로카테킨 갈레이트를 분리정제하는 방법은, 상기 1)단계와 2)단계 사이에 추가로, 충전제로서 그 크기가 100㎛인 충전제를 충전 매질로 사용한 C-18 ODS 칼럼을 이용하는 단계를 포함할 수 있다. In addition, the method for separating and purifying epigallocatechin gallate of the present invention further comprises a C-18 ODS column using a filler having a size of 100 μm as a filling medium between the steps 1) and 2). It may include the step of using.
그렇지 않으면, 본 발명의 방법은, 상기 실리카겔에 디클로로메틸 실란을 결합시킨 충전제로서 그 크기가 100 ㎛인 충전제를 충전 매질로 사용한 칼럼에, 충전제로서 그 크기가 100㎛인 충전제를 충전 매질로 사용한 C-18 ODS 칼럼을 추가로 직렬로 연결하여 에피갈로카테킨 갈레이트를 분리정제할 수 있다.Otherwise, the method of the present invention, C, using a filler having a size of 100 μm as a filling medium as a filler in which dichloromethyl silane is bonded to the silica gel, and a filler having a size of 100 μm as a filler as a filler medium Epigallocatechin gallate can be separated and purified further by connecting an -18 ODS column in series.
한편, 상기 용리액은 바람직하게는 0.5~1.0v/v% 아세트산 수용액 또는 5.0~10.0v/v% 에탄올 수용액이다.On the other hand, the eluent is preferably 0.5 ~ 1.0v / v% aqueous acetic acid solution or 5.0 ~ 10.0v / v% ethanol aqueous solution.
그리고, 상기 실리카겔에 디클로로메틸 실란을 결합시킨 충전제로서 그 크기가 100 ㎛인 충전제를 충전 매질로 사용한 칼럼은, 예를 들면 바람직하게는 DM 1020 칼럼(100 ㎛)이다. In addition, a column in which a filler having a size of 100 μm as a filling medium as a filler in which dichloromethyl silane is bonded to the silica gel is preferably, for example, a DM 1020 column (100 μm).
예를 들어, 하기의 단계들에 의해, 90% 이상의 고순도 에피갈로카테킨 갈레 이트를 빠른 시간 내에 많은 양을 얻을 수 있다:For example, by the following steps, a high amount of at least 90% high purity epigallocatechin gallate can be obtained in a short time:
1) 에피갈로카테킨 갈레이트 52%를 함유하는 녹차 추출물을 물 또는 0.1~2.0v/v% 아세트산 수용액에 용해시킨 후, 상기 용액을 실리카겔에 디클로로메틸 실란을 결합시킨 충전제로서 그 크기가 100 ㎛인 충전제 DM 1020(일본 시세이도 화인 화학사(Shiseido fine chemicals))을 충전 매질로 사용한 칼럼(이하, ‘DM 1020 칼럼’이라 칭한다)에 로딩하고, 0.1~2.0v/v% 아세트산 수용액 또는 1.0~10.0v/v% 에탄올 수용액으로 용출시켜, 녹차 추출물에 함유된 비극성 물질 등을 분리하는 단계,1) A green tea extract containing 52% epigallocatechin gallate was dissolved in water or an aqueous solution of 0.1-2.0v / v% acetic acid, and the solution was a filler in which dichloromethyl silane was bonded to silica gel and its size was 100 μm. Phosphorus filler DM 1020 (Shiseido Fine Chemicals, Japan) was loaded onto a column using a filling medium (hereinafter referred to as a DM 1020 column), and 0.1-2.0v / v% acetic acid aqueous solution or 1.0-10.0v. eluting with an aqueous solution of / v% ethanol to separate the non-polar substances contained in the green tea extract,
2) 상기 1)단계의 DM 1020 칼럼에서 분획된 에피갈로카테킨 갈레이트와 에피카테킨 갈레이트를 C-18 ODS 칼럼에 로딩하고, 0.1~2.0v/v% 아세트산 수용액 또는 1.0~10.0v/v% 에탄올 수용액으로 용출시켜 에피갈로카테킨 갈레이트와 에피카테킨 갈레이트를 분리하는 단계,2) The epigallocatechin gallate and epicatechin gallate fractionated in the DM 1020 column of step 1) are loaded on a C-18 ODS column, and 0.1 to 2.0 v / v% aqueous acetic acid solution or 1.0 to 10.0 v / v%. Eluting with an ethanol aqueous solution to separate epigallocatechin gallate and epicatechin gallate,
3) 상기 2)단계에서 분획된 에피갈로카테킨 갈레이트를 에틸아세테이트로 추출하고, 농축하여 얻어진 농축물을 0.1~2.0v/v% 아세트산 수용액에 용해시켜 재결정하는 단계. 3) extracting the epigallocatechin gallate fractionated in step 2) with ethyl acetate, and concentrating and recrystallizing the concentrate obtained by dissolving in 0.1-2.0 v / v% acetic acid aqueous solution.
원료로 사용되는 녹차 추출물의 제조는 일반화 되어 상품(Huzhou Chengma Biological and chemical co. ltd., China)으로 쉽게 구할 수 있으며, 이 원료의 구성은 표 1과 같다.The production of green tea extract used as a raw material is generalized and can be easily obtained as a commodity (Huzhou Chengma Biological and chemical co. Ltd., China). The composition of this raw material is shown in Table 1.
상기 추출물의 카테킨의 함량은 82%이며, HPLC에 의한 에피갈로카테킨 갈레이트와 에피카테킨 갈레이트의 함량은 각각 52%와 16%였다. 추출물의 카테킨 성분 비율에서 알 수 있듯이 에피갈로카테킨 갈레이트를 정제 분리하는데 있어서, 에피갈로카테킨 갈레이트와 유사한 구조를 가지면서 에피갈로카테킨 갈레이트 다음으로 많은 양이 포함되어 있는 에피카테킨 갈레이트와의 분리가 중요하다. 또한 원료로 사용된 녹차 추출물은 제조시 제거되지 못한 카페인을 비롯하여 에피갈로카테킨 갈레이트보다 비극성인 많은 물질들이 함유되어 있으며, 또한 이들은 미세한 형태의 입자를 이루고 있어 일반 여과 과정이나 원심분리 등에 의해 쉽게 분리되지 않는 불용성이다.The catechin content of the extract was 82%, and epigallocatechin gallate and epicatechin gallate content by HPLC were 52% and 16%, respectively. As can be seen from the catechin component ratio of the extract, in the purification and separation of epigallocatechin gallate, epicatechin gallate has a similar structure to epigallocatechin gallate and contains the second largest amount after epigallocatechin gallate. Separation from is important. In addition, the green tea extract used as a raw material contains many substances which are more non-polar than epigallocatechin gallate, including caffeine, which was not removed during manufacture, and they are easily formed by general filtration or centrifugation because they form fine particles. It is insoluble and inseparable.
본 발명자들은 DM 1020 매질이 비극성 녹차 성분들의 제거 및 에피갈로카테킨 갈레이트와 에피카테킨 갈레이트의 분리에 효과적인 역상모드 충전제임을 발견하였다. DM 1020은 실리카겔에 디클로로디메틸 실란을 결합시킨 매질로 구조는 도 2에 나타내었다. The inventors have found that DM 1020 medium is an inverse phase filler which is effective in removing non-polar green tea components and separating epigallocatechin gallate and epicatechin gallate. DM 1020 is a medium in which dichlorodimethyl silane is bonded to silica gel, and the structure thereof is shown in FIG. 2.
또한 DM 1020 충전제은 C-18 충전제보다 가격면에서 1/5 수준으로 저렴하여 DM 1020 칼럼 단독으로 또는 DM 1020 칼럼과 C-18 ODS 칼럼을 직렬로 연결하여, 에 피갈로카테킨 갈레이트의 분리에 적용시키는 것은 경제적인 면과 생산성면에서 C-18 ODS 칼럼의 단점을 보완할 수 있다. In addition, DM 1020 filler is 1/5 cheaper than C-18 filler, so it can be applied to the separation of epigallocatechin gallate by using DM 1020 column alone or connecting DM 1020 column and C-18 ODS column in series. This can compensate for the disadvantages of C-18 ODS columns in terms of economics and productivity.
충전제과 녹차 추출물의 무게에 있어서, DM 1020 칼럼을 단독으로 사용할 때는, 예를 들면 분리하려는 녹차 추출물의 무게의 15 내지 20배의 충전제를 사용할 수 있고, DM 1020 칼럼과 C-18 ODS 칼럼을 직렬로 연결하여 사용할 때에는, 예를 들면 DM 1020 충전제은 녹차 추출물 무게에 대해 동량(同量)을, C-18 충전제은 녹차 추출물의 무게의 4 내지 5배를 사용할 수 있다. 칼럼의 재생은, 예를 들면 70% 메탄올, 50% 에탄올 수용액 또는 50% 이소프로판올을 용출시킨 후, 재사용할 수 있다.In the weight of the filler and green tea extract, when using the DM 1020 column alone, for example, a filler of 15 to 20 times the weight of the green tea extract to be separated can be used, and the DM 1020 column and the C-18 ODS column are serialized. When used in conjunction with, for example, DM 1020 filler may be used in the same amount relative to the weight of the green tea extract, C-18 filler may be used 4 to 5 times the weight of the green tea extract. Regeneration of the column can be reused, for example after eluting 70% methanol, 50% ethanol aqueous solution or 50% isopropanol.
본 발명에서는 에피갈로카테킨 갈레이트가 물에서 쉽게 분해되는 것을 방지하기 위해 소량의 아세트산을 첨가함으로써 에피갈로카테킨 갈레이트의 안정성을 유지할 수 있다. In the present invention, it is possible to maintain the stability of epigallocatechin gallate by adding a small amount of acetic acid in order to prevent the decomposition of epigallocatechin gallate in water easily.
이하, 본 발명을 실시예를 통해 더욱 상세히 기술하고자 한다. 다만, 하기 실시예는 본 발명을 구체적으로 설명하는 것으로서, 하기 실시예에 의해 본 발명의 범위가 제한되지는 않는다. Hereinafter, the present invention will be described in more detail with reference to Examples. However, the following examples illustrate the present invention in detail, and the scope of the present invention is not limited by the following examples.
실험 재료 및 방법Experimental Materials and Methods
DM 1020(100 ㎛)는 일본 시세이도 화인 화학사, C-18 ODS(100 ㎛)는 일본 타임리사(timely.co.,LTD)에서 구입하였고, 녹차 추출물은 중국 후조우 쳉마 생명 및 화학사(Huzhou Chengma Biological and chemical co. ltd.)에서 구입하여 사용하였다.DM 1020 (100 μm) was purchased from Shiseido Fine Chemicals, Japan, and C-18 ODS (100 μm) was purchased from Timely.co., LTD., Japan. Green tea extracts were obtained from Huzhou Chengma Biological, China. and chemical co. ltd.).
에피갈로카테킨 갈레이트 분리 과정 중 에피갈로카테킨 갈레이트의 확인은 TLC와 HPLC로 실시하였다. Epigallocatechin gallate was identified during epigallocatechin gallate separation by TLC and HPLC.
TLC 분석조건 TLC analysis conditions
TLC plate: 실리카겔 60 F254(미국 머크사)TLC plate: Silica gel 60 F254 (Merck, USA)
전개용매: 헥산/에틸 아세테이트(v/v = 1/3.5)Developing solvent: hexane / ethyl acetate (v / v = 1 / 3.5)
HPLC 분석조건 HPLC analysis conditions
HPLC 용매 : 0.4% 인산/ 27% 메탄올 수용액HPLC solvent: 0.4% phosphoric acid / 27% aqueous methanol solution
속도 : 1.0 ㎖/minSpeed: 1.0 ml / min
검출기 : UV(284 nm)Detector: UV (284 nm)
칼럼 : 0.45 ㎛ ×15 cm, C18 칼럼(캅셀팍(capcellpak): 일본 시세이도 화인 화학사)Column: 0.45 μm × 15 cm, C18 column (capcelpak: Shiseido Fine Chemicals, Japan)
실시예 1Example 1
에피갈로카테킨 갈레이트 26 g을 함유하는 녹차 추출물 50 g을 50 ㎖의 물에 녹인 후, DM 1020 1 kg이 충전된 DM 1020 칼럼에 로딩하였다. 1.0v/v% 아세트산 수용액을 100 ㎖/min의 속도로 2.5 ℓ용출시킨 후, 상기 용출액을 50 ㎖로 농축하였다.50 g of green tea extract containing 26 g of epigallocatechin gallate was dissolved in 50 ml of water and then loaded onto a DM 1020 column filled with 1 kg of DM 1020. The aqueous solution of 1.0v / v% acetic acid was eluted at 2.5 L at a rate of 100 mL / min, and the eluate was concentrated to 50 mL.
상기 농축물을 에틸아세테이트(100 ㎖ ×2)로 추출하고, 에틸아세테이트를 감압하에서 제거하여 얻은 농축물을 1.0v/v% 아세트산 수용액 70㎖에 녹여 2차례 재결정하였다. 15.3 g의 흰색의 에피갈로카테킨 갈레이트를 얻었다. HPLC 분석 결과는 에피갈로카테킨 갈레이트가 94%, 수분은 3.5%이었다.The concentrate was extracted with ethyl acetate (100 mL × 2), and the concentrate obtained by removing the ethyl acetate under reduced pressure was dissolved in 70 mL of 1.0v / v% acetic acid aqueous solution and recrystallized twice. 15.3 g of white epigallocatechin gallate was obtained. HPLC analysis showed that epigallocatechin gallate was 94% and moisture was 3.5%.
실시예 2Example 2
에피갈로카테킨 갈레이트 520 g을 함유하는 녹차 추출물 1 kg을 1.0v/v% 아세트산 수용액 3 ℓ에 녹이고, DM 1020 칼럼(100 ㎛, 3 kg)에 로딩한 후, 100 ㎖/min의 유속으로 1.0v/v% 아세트산 수용액을 흘려, 10 ℓ를 용출시켜 농축하여 50 브릭스(brix.)의 농축물을 얻었다. 1 kg of green tea extract containing 520 g of epigallocatechin gallate was dissolved in 3 l of 1.0v / v% acetic acid aqueous solution, loaded on a DM 1020 column (100 μm, 3 kg), and then at a flow rate of 100 ml / min. A 1.0 v / v% acetic acid aqueous solution was poured, and 10 L was eluted and concentrated to obtain a concentrate of 50 brix.
상기 농축물을 C-18 ODS 칼럼(100 mesh, 5kg)에 로딩한 후 1.0v/v% 아세트산수용액으로 유속 800 ㎖/min으로 흘려 40 ℓ를 용출하였다. 상기 용출액을 1 ℓ로 농축하고, 에틸아세테이트 (2 ℓ×3)로 추출하고, 에틸아세테이트 분획을 농축한 후 1.0v/v% 아세트산 수용액으로 재결정하여, 1차로 250 g을, 2차로 87.5 g을 얻었다(337.5 g, 65%). HPLC 분석 결과는 에피갈로카테킨 갈레이트가 93%, 수분은 3.3% 이었다. 칼럼은 50% 에탄올 수용액 10 ℓ를 용출시킨 후, 재사용하였다.The concentrate was loaded on a C-18 ODS column (100 mesh, 5 kg), and then 40 L was eluted with 1.0 v / v% acetic acid solution at a flow rate of 800 ml / min. The eluate was concentrated to 1 L, extracted with ethyl acetate (2 L × 3), the ethyl acetate fractions were concentrated and recrystallized with 1.0v / v% acetic acid aqueous solution, 250 g of primary, 87.5 g of secondary Obtained (337.5 g, 65%). HPLC analysis showed that epigallocatechin gallate was 93% and moisture 3.3%. The column was eluted with 10 L of 50% aqueous ethanol solution and then reused.
실시예 3Example 3
실시예 2와 동일한 방법으로 실시하였다. 에피갈로카테킨 갈레이트 520 g을 함유하는 녹차 추출물 1 kg을 0.5v/v% 아세트산 수용액 3 ℓ에 녹여 DM 1020 칼럼에 로딩한 후, 100 ㎖/min의 유속으로 5v/v% 에탄올 수용액을 5 ℓ용출시켜 50 브릭스로 농축하였다. It carried out in the same manner as in Example 2. 1 kg of green tea extract containing 520 g of epigallocatechin gallate was dissolved in 3 l of an aqueous 0.5v / v% acetic acid solution and loaded on a DM 1020 column, followed by 5v / v% aqueous ethanol solution at a flow rate of 100 ml / min. Eluate and concentrate to 50 brix.
상기 농축물을 C-18 ODS 칼럼에 로딩하고, 1.0v/v% 아세트산 수용액을 800 ㎖/min의 유속으로 10 ℓ용출시킨 후, 5v/v% 에탄올 수용액으로 20 ℓ용출시켰다. 용출액을 1 ℓ로 농축하여 에틸아세테이트로 추출하고 농축한 후, 1.0% 아세트산 수용액으로 재결정하여 389 g의 흰색 고체를 얻었다. HPLC 분석 결과는 에피갈로카테킨 갈레이트가 92%, 수분은 4.4%이었다.The concentrate was loaded on a C-18 ODS column and eluted with 1.0 l / v% acetic acid solution at a flow rate of 800 ml / min, followed by 20 l with 5 v / v% ethanol aqueous solution. The eluate was concentrated to 1 L, extracted with ethyl acetate, concentrated, and recrystallized with 1.0% acetic acid aqueous solution to obtain 389 g of a white solid. HPLC analysis showed that Epigallocatechin gallate was 92% and moisture was 4.4%.
실시예 4Example 4
추가로 C-18 ODS 칼럼을 상기 DM 1020 칼럼에 직렬로 연결하고, 에피갈로카테킨 갈레이트 520 g을 함유하는 녹차 추출물 1 kg을 1.0v/v% 아세트산 수용액 2.0 ℓ에 녹인 후 상기 직렬로 연결된 칼럼에 로딩하였다. 로딩이 끝난 후 1.0v/v% 아세트산 수용액을 800 ㎖/min으로 용출하였다. 10 ℓ를 용출시킨 후 DM 1020 칼럼을 C-18 ODS 칼럼과 분리시키고 C-18 ODS 칼럼을 1.0v/v% 아세트산 수용액으로 800 ㎖ /min으로 흘려 40 ℓ를 더 용출시켰다.Further, a C-18 ODS column was connected in series to the DM 1020 column, 1 kg of green tea extract containing 520 g of epigallocatechin gallate was dissolved in 2.0 L of 1.0v / v% acetic acid solution, and then connected in series. Loaded on the column. After the loading was completed, 1.0 v / v% acetic acid aqueous solution was eluted at 800 ml / min. After dissolving 10 L, the DM 1020 column was separated from the C-18 ODS column, and 40 C was further eluted by flowing the C-18 ODS column at 800 mL / min with an aqueous 1.0v / v% acetic acid solution.
용출액을 합하여 2 ℓ로 농축시키고 에틸아세테이트로 추출한 후, 1.0v/v% 아세트산 수용액으로 재결정하여 357 g의 흰색고체를 얻었다. HPLC 분석 결과는 에피갈로카테킨 갈레이트가 92%, 수분은 4.5%이었다.The combined eluates were concentrated to 2 L, extracted with ethyl acetate, and recrystallized with 1.0 v / v% acetic acid aqueous solution to obtain 357 g of a white solid. HPLC analysis showed that epigallocatechin gallate was 92% and moisture 4.5%.
비교예 1Comparative Example 1
0.3 내지 1.2 mm의 입자크기를 가지는 암베라이트 XAD-7 수지 33.5 ℓ(26 kg)을 내경 150 mm, 길이 2 m 규모의 칼럼 내로 충전하였다. 상기 칼럼에 가열재킷을 장치하고, 충전된 칼럼을 60℃로 항온 유지시켰다. 0.4 kg의 녹차추출물(에피갈로카테킨 갈레이트로서 152.5 g)을 물/이소프로판올(부피비 9:1)의 혼합물 1.8 kg에 용해시키고 상기 칼럼의 상부에 도입하였다. 0.5 bar의 압력 및 60℃의 온도 하에서 50 kg/h 의 유속으로 물/이소프로판올(부피비 9:1)의 혼합물을 펌프하여 에피갈로카테킨 갈레이트를 용출시켰다.33.5 L (26 kg) of Amberlite XAD-7 resin having a particle size of 0.3 to 1.2 mm was charged into a column having a diameter of 150 mm and a length of 2 m. The column was equipped with a heating jacket and the packed column was kept at 60 ° C. 0.4 kg of green tea extract (152.5 g as epigallocatechin gallate) was dissolved in 1.8 kg of a mixture of water / isopropanol (volume 9: 1) and introduced to the top of the column. Epigallocatechin gallate was eluted by pumping a mixture of water / isopropanol (volume ratio 9: 1) at a pressure of 0.5 bar and a flow rate of 50 kg / h at a temperature of 60 ° C.
144 kg의 초기 용출 후, 에피갈로카테킨 갈레이트 112 g을 함유하는 용출액 174 kg을 회수하였다. 주요 용출액 중 에피갈로카테킨 갈레이트의 농도는 0.064%였다. 분리된 에피갈로카테킨 갈레이트의 수율은 73.5%였다. 수지 재생을 위해 잔류하는 카테킨을 물/이소프로판올(부피비 4:6)의 혼합물 78.3 kg으로 용출시켰다.After an initial elution of 144 kg, 174 kg of eluate containing 112 g of epigallocatechin gallate was recovered. The epigallocatechin gallate concentration in the main eluate was 0.064%. The yield of isolated epigallocatechin gallate was 73.5%. The remaining catechins for resin regeneration were eluted with 78.3 kg of a mixture of water / isopropanol (volume ratio 4: 6).
비교예 2Comparative Example 2
입자크기가 4 내지 5 마이크론인 폴리아마이트11 충전제 250 g을 에틸 아세테이트 300 ㎖에 현탁시키고, 내부직경 5 cm, 길이 36 cm인 칼럼 내로 옮겼다. 상기 칼럼을 가열재킷으로 장치하고, 40℃로 항온유지하였다. 3 g의 녹차추출물(에피갈로카테킨 갈레이트로서 1.11 g)을 에틸 아세테이트 153 mg에 용해시키고 칼럼 상부에 도입하였다. 0.3 bar의 압력하에 500 ㎖의 에틸 아세테이트, 1000 ㎖의 에틸 아세테이트/에탄올 (부피비 8.5/1.5) 1000 ㎖의 에틸 아세테이트/에탄올(부피비 7:3), 2000 ㎖의 에틸 아세테이트/에탄올(부피비 1:1)로 용출시켜, 주요 분획물 550 ㎖을 농축하여 0.87 g의 에피갈로카테킨 갈레이트를 함유하는 고체 1.12 g을 얻었다. 주요 용출액 중 에피갈로카테킨 갈레이트의 농도는 0.186%였다. 분리된 에피갈로카테킨 갈레이트의 수율은 76%였다.250 g of polyamide 11 filler having a particle size of 4 to 5 microns was suspended in 300 ml of ethyl acetate and transferred into a column 5 cm in diameter and 36 cm in length. The column was set up with a heating jacket and kept at 40 ° C. 3 g green tea extract (1.11 g as epigallocatechin gallate) was dissolved in 153 mg of ethyl acetate and introduced at the top of the column. 500 ml of ethyl acetate under pressure of 0.3 bar, 1000 ml of ethyl acetate / ethanol (volume ratio 8.5 / 1.5) 1000 ml of ethyl acetate / ethanol (volume ratio 7: 3), 2000 ml of ethyl acetate / ethanol (volume ratio 1: 1) Eluting) concentrated 550 ml of the main fraction to give 1.12 g of a solid containing 0.87 g of epigallocatechin gallate. Epigallocatechin gallate concentration in the main eluate was 0.186%. The yield of isolated epigallocatechin gallate was 76%.
비교예 3Comparative Example 3
0.3~1.2 mm 이하의 입자 크기인 암베라이트 XAD-7 충전제 450 ㎖를 내부직경 2.4 cm, 길이 100 cm인 칼럼에 충전시키고, 물/에탄올(부피비 9:1)로 씻어내고, 초기 용리액인 물/에탄올(부피비 9:1)로 안정화시켰다. 20 g의 녹차추출물(에피갈로카테킨 갈레이트로서 2.91 g)을 60℃로 유지시키며 용리액을 흘려주었다. 초기 용리액 2.48 ℓ를 흘려 준 후, 4.95 ℓ의 용출액을 얻었다. 에피갈로카테킨 갈레이트의 농도는 0.47 g/ℓ이며 에피갈로카테킨 갈레이트의 순도는 86.1%였다.450 ml of Amberlite XAD-7 filler having a particle size of 0.3-1.2 mm or less was charged into a column having an internal diameter of 2.4 cm and a length of 100 cm, washed with water / ethanol (volume ratio 9: 1), and the initial eluent of water / Stabilized with ethanol (volume 9: 1). 20 g of green tea extract (2.91 g as epigallocatechin gallate) was kept at 60 ° C. and the eluent was flowed. After flowing 2.48 L of the initial eluent, 4.95 L of the eluent was obtained. Epigallocatechin gallate had a concentration of 0.47 g / l and epigallocatechin gallate had a purity of 86.1%.
통상의 방법에 의해 에피갈로카테킨 갈레이트를 분리하는 경우에는 설비에 가온장치의 부착 및 다량의 용매사용으로 농축설비의 거대화 등이 문제점으로 대두되나, 본 발명의 공정에 의해 에피갈로카테킨 갈레이트를 분리정제하는 경우에는 90% 이상의 고순도를 가지는 에피갈로카테킨 갈레이트를 경제적이고, 실용적으로 대량분리가 가능하며, 화장품, 식품 및 의약용 원료로 사용 가능한 바, 본 발명은 매우 유용한 발명이다.When epigallocatechin gallate is separated by a conventional method, problems such as the attachment of a heating device to the facility and the enlarging of the concentration facility due to the use of a large amount of solvents are a problem. When separating and refining the rate, epigallocatechin gallate having a high purity of 90% or more can be economically and practically separated in bulk, and can be used as a raw material for cosmetics, food, and medicine, and the present invention is a very useful invention. .
본 발명에 따라 녹차 추출물로부터 고순도의 에피갈로카테킨 갈레이트를 경제적이며, 생산성이 높게 분리할 수 있다. According to the present invention, high purity epigallocatechin gallate can be separated from green tea extract economically and with high productivity.
또한, 본 발명의 공정은 실리카겔에 디클로로메틸실란을 결합시킨 충전제(DM 1020)를 이용한 칼럼에 녹차추출물을 로딩하고, 아세트산 수용액을 용리액으로 이용하여 90% 이상의 고순도 에피갈로카테킨 갈레이트를 경제적이고, 실용적으로 대량분리 생산하는 공정이며, 아세트산, 에탄올, 에틸아세테이트 등 식품제조에 사용할 수 있는 안전성이 확보된 에피갈로카테킨 갈레이트의 분리정제 제조방법이다. In addition, the process of the present invention is loaded with green tea extract on a column using a filler (DM 1020) in which dichloromethylsilane is bonded to silica gel, and using an acetic acid aqueous solution as an eluent, high purity epigallocatechin gallate of 90% or more It is a process for producing large-scale separated production, and it is a method for preparing separated tablets of epigallocatechin gallate which has a safety which can be used for food production such as acetic acid, ethanol, ethyl acetate and the like.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040097357A KR100690928B1 (en) | 2004-11-25 | 2004-11-25 | Method for separation and purification of epigallocatechin gallate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040097357A KR100690928B1 (en) | 2004-11-25 | 2004-11-25 | Method for separation and purification of epigallocatechin gallate |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060058356A KR20060058356A (en) | 2006-05-30 |
KR100690928B1 true KR100690928B1 (en) | 2007-03-09 |
Family
ID=37153442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040097357A KR100690928B1 (en) | 2004-11-25 | 2004-11-25 | Method for separation and purification of epigallocatechin gallate |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100690928B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100859579B1 (en) | 2006-11-20 | 2008-09-23 | 재단법인 제주하이테크산업진흥원 | Method for Extracting Catechin from Green Tea |
KR20210032224A (en) | 2019-09-16 | 2021-03-24 | (주)알앤오식품 | Mass-production method of decaffeined and highly pure epigallocatechin gallate from green tea extract |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104557839A (en) * | 2014-12-24 | 2015-04-29 | 浙江远圣茶业有限公司 | Preparation method and application of EGCG-Zn complex |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613672A (en) | 1983-07-05 | 1986-09-23 | Mitsu Norin Co., Ltd. | Process for the production of tea catechins |
KR100307437B1 (en) | 1998-10-14 | 2001-12-28 | 조양호 | Method for extracting and purifying anticancer component from green tea |
KR20030010011A (en) * | 2001-07-25 | 2003-02-05 | (주)엔바이오솔루션 | A process of extraction of epigallocatechin gallate from green tea |
KR100418605B1 (en) | 2001-12-05 | 2004-02-14 | 주식회사 태평양 | Process for the production of high purified (-)Epigallocatechin Gallate from Green tea extract |
-
2004
- 2004-11-25 KR KR1020040097357A patent/KR100690928B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613672A (en) | 1983-07-05 | 1986-09-23 | Mitsu Norin Co., Ltd. | Process for the production of tea catechins |
KR100307437B1 (en) | 1998-10-14 | 2001-12-28 | 조양호 | Method for extracting and purifying anticancer component from green tea |
KR20030010011A (en) * | 2001-07-25 | 2003-02-05 | (주)엔바이오솔루션 | A process of extraction of epigallocatechin gallate from green tea |
KR100418605B1 (en) | 2001-12-05 | 2004-02-14 | 주식회사 태평양 | Process for the production of high purified (-)Epigallocatechin Gallate from Green tea extract |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100859579B1 (en) | 2006-11-20 | 2008-09-23 | 재단법인 제주하이테크산업진흥원 | Method for Extracting Catechin from Green Tea |
KR20210032224A (en) | 2019-09-16 | 2021-03-24 | (주)알앤오식품 | Mass-production method of decaffeined and highly pure epigallocatechin gallate from green tea extract |
Also Published As
Publication number | Publication date |
---|---|
KR20060058356A (en) | 2006-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1077211B1 (en) | Process for the production of epigallocatechin gallate | |
CN110330409B (en) | Preparation method of industrial hemp extract | |
CN107011125A (en) | A kind of method for being enriched with cannabidiol | |
US6210679B1 (en) | Method for isolation of caffeine-free catechins from green tea | |
JP5593031B2 (en) | Grape seed extract obtained by fractionation with resin | |
KR20100136978A (en) | Extract from oil palm leaves comprising phenolic acids | |
KR101603733B1 (en) | Method for extracting maysin and bioactive compounds with high yield from corn silk | |
JP3052172B2 (en) | Method for producing tea catechins | |
KR100690928B1 (en) | Method for separation and purification of epigallocatechin gallate | |
KR101072447B1 (en) | Extraction method of catechin from green tea leaves | |
CN103910705B (en) | The method of rapid extraction separation and purification NVP-XAA 723 from the tankage of green tea | |
KR101123102B1 (en) | Method for separation and purification of EGCG from Camellia sinensis leaf by ultra high pressure recrystallization | |
JPWO2003091237A1 (en) | Method for producing high content of proanthocyanidins | |
JP2012005413A (en) | Method for preparing fermented tea extract containing polymer polyphenol | |
KR20070074718A (en) | Theanine extraction process from green tea | |
FR2944970A1 (en) | PROCESS FOR THE PREPARATION OF POLYPHENOLIC EXTRACTS FROM SPINACH LEAVES | |
US7863466B2 (en) | Method of producing proanthocyanidin-containing material | |
KR100418605B1 (en) | Process for the production of high purified (-)Epigallocatechin Gallate from Green tea extract | |
KR20020015805A (en) | Extracting process of highly purified natural rutin from buckwheat | |
CN106632207B (en) | A kind of preparation method of high-purity GCG | |
JP6400882B2 (en) | Blood sugar level control agent containing specific cocoa polyphenol as active ingredient, and method for producing specific cocoa polyphenol | |
US20080249163A1 (en) | Process For Producing Product Containing Proanthocyanidin in High Proportion | |
KR101635823B1 (en) | Method for separation and purification of catechin derivatives from tea leaf | |
JPWO2005070443A1 (en) | Bark extract | |
CN113559139A (en) | Total coumarin extract from sunflower disc and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120312 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141224 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160317 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170324 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180320 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190219 Year of fee payment: 13 |